Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 1600-1601, 2002;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mariën, G.
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mariën, G.
Right arrow Articles by Bossuyt, X.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:1600-1601.)
© 2002 American Association for Clinical Chemistry, Inc.


Technical Briefs

Detection of Monoclonal Proteins in Sera by Capillary Zone Electrophoresis and Free Light Chain Measurements

Godelieve Mariën1, Els Oris1, Arthur R. Bradwell2, Norbert Blanckaert1 and Xavier Bossuyt1a

1 Laboratory Medicine, Immunology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium;
2 Department of Immunology, University of Birmingham, The Medical School, Birmingham B15 2TJ, United Kingdom

aaddress correspondence to this author at: Laboratoriumgeneeskunde, Immunologie, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium; fax 32-16-347-931, e-mail Xavier.bossuyt{at}uz.kuleuven.ac.be

Capillary zone electrophoresis (CZE) is increasingly used in clinical laboratories for serum protein separation. The technique is a sensitive method for the detection of monoclonal (M) proteins. However, when compared with immunofixation, CZE fails to detect M proteins in 5% of samples (1)(2). These so-called "false-negative" results encompass low-concentration and "hidden" M proteins (e.g., in the transferrin peak).

The goal of this study was to evaluate whether an assay for the detection of free light chains (FLCs) that has recently become available (Freelite®; The Binding Site) can detect the M proteins present in samples that produce false-negative results in CZE. The Freelite assay is a sensitive automated immunoassay for {kappa} and {lambda} FLCs in serum (3) and has been useful for the diagnosis and monitoring of patients with nonsecretory myeloma (4). Moreover, it has been reported that the quantification of FLCs in serum by nephelometry correlates with changes in urinary FLC excretion (5).

Frozen sera from 54 patients that had previously been shown to contain M proteins by immunofixation (Sebia), but not by CZE (Paragon 2000TM CZE, software Ver. 1.5; Beckman-Coulter), were assayed by nephelometry (Immage; Beckman-Coulter) for FLCs (Freelite). All assays were performed according to the manufacturers’ instructions. The M proteins were of various types and included examples of both intact immunoglobulins and FLCs. The samples were from patients with (a) (chronic) immune stimulation [n = 7; Sjögren syndrome, polyarteritis, pneumonia, Staphylococcus aureus sepsis, chronic hepatitis B infection, post-renal transplantation (n = 2)], (b) monoclonal gammopathy of unknown significance (MGUS; n = 8), (c) primary (AL) amyloidosis (n = 1), and (d) B-cell-derived malignant disease (n = 34). The last group included patients with multiple myeloma (n = 20), smoldering myeloma (n = 1), plasma cell leukemia (n = 1), plasmacytoma (n = 3), and lymphoproliferative disease, including Waldenström macroglobulinemia (n = 2), non-Hodgkin lymphoma (n = 6), and chronic lymphocytic leukemia (n = 1). Eleven of the 34 patients with B-cell-derived malignant disease had received a transplant. For four patients, medical records could not be consulted.

Sera from 20 controls were analyzed as well. The free {kappa}/free {lambda} ratios for these samples were within the reference interval as specified by the manufacturer (0.359–1.01).

The results of the free {kappa} and free {lambda} quantification are shown in Fig. 1 . Sera from patients with free {kappa} light chain M proteins (n = 9) all showed an increased free {kappa}/{lambda} ratio (between 9.5 and 793) and increased absolute values for the relevant free {kappa} chain. Sera from patients with free {lambda} light chain M proteins (n = 12) all showed a low free {kappa}/{lambda} ratio (between 0.001 and 0.036) and increased concentrations of the relevant free {lambda} chain. In 16 of these samples in which monoclonal FLCs were present, quantification of total {kappa} and {lambda} was performed by nephelometry using Beckman-Coulter reagents on the Immage instrument. Quantification of the FLCs revealed an abnormal free {kappa}/free {lambda} ratio in all samples, whereas quantification of the total light chains revealed an abnormal {kappa}/{lambda} ratio in only 5 of the 16 samples (data not shown).



View larger version (14K):
[in this window]
[in a new window]
 
Figure 1. {kappa} and {lambda} FLC concentrations in 20 control samples and in 55 samples that displayed a normal CZE electropherogram but in which immunofixation revealed a small M protein.

Samples in which immunofixation revealed a FLC M protein are shown as filled squares. Samples in which immunofixation revealed the presence of an intact monoclonal protein are indicated by crosses ({lambda}-type intact M protein) or open triangles ({kappa}-type intact M proteins). The control samples are represented by gray circles.

Of 12 sera from patients with an intact immunoglobulin M protein of {kappa} type (1 IgG, 6 IgA, and 5 IgM), only 4 had an increased free {kappa}/{lambda} ratio (between 1.5 and 5.2). Nine of 21 sera from patients with an intact immunoglobulin M protein of {lambda} type (6 IgG, 8 IgA, 6 IgM, and 1 IgD) had decreased free {kappa}/{lambda} ratios (between 0.037 and 0.2).

The distribution of diagnoses with an indication of the number of abnormal FLC ratios is shown in Table 1 . Of seven patients with chronic stimulation of the immune system, the free {kappa}/free {lambda} ratio was abnormal in four (57%). In one of these four cases, the ratio was only modestly increased (1.09). In patients with MGUS and B-cell-derived malignant disease, the free {kappa}/{lambda} ratio was abnormal in 75% and 71%, respectively. Concentrations of both free {kappa} and free {lambda} were increased in five of the seven patients (71%) with chronic immune stimulation. By contrast, concentrations of both free {kappa} and free {lambda} were increased in only 7 of the 43 patients (16%) with MGUS, B-cell-derived malignancy, or primary amyloidosis.


View this table:
[in this window]
[in a new window]
 
Table 1. Distribution of diagnoses with indication of number of abnormal FLCs.

In conclusion, FLC nephelometric measurement in serum seems to be a convenient assay for detection of FLC M proteins in serum. This technique is more reliable than CZE and nephelometric measurement of total {kappa} and {lambda}. For intact immunoglobulin M proteins, the free {kappa}/{lambda} ratio was within reference values in 60% of the cases in which CZE failed to detect an M protein. Future studies should address the question whether the presence of increased FLCs together with a low concentration intact immunoglobulin M protein has a prognostic clinical value.


References

  1. Katzman JA, Clark R, Sanders E, Landers JP, Kyle RA. Prospective study of serum protein capillary electrophoresis immunotyping of monoclonal proteins by immuno-subtraction. Am J Clin Pathol 1998;110:503-509.[ISI][Medline] [Order article via Infotrieve]
  2. Bossuyt X, Mariën G. False-negative results in detection of monoclonal proteins by capillary zone electrophoresis: a prospective study. Clin Chem 2001;47:1477-1479.[Free Full Text]
  3. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:637-680.
  4. Drayson M, Tang LX, Drew R, Mead G, Carr-Smith H, Bradwell AR. Serum free light-chain measurement for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2902.[Abstract/Free Full Text]
  5. Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002;48:655-657.[Free Full Text]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mariën, G.
Right arrow Articles by Bossuyt, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mariën, G.
Right arrow Articles by Bossuyt, X.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS